<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02737865</url>
  </required_header>
  <id_info>
    <org_study_id>2015-10-134-003</org_study_id>
    <nct_id>NCT02737865</nct_id>
  </id_info>
  <brief_title>Superb Microvascular Imaging in Focal Nodular Hyperplasia</brief_title>
  <official_title>&quot;The Fingerprint: Spoke-wheel Sign&quot; of Focal Nodular Hyperplasia: Assessment of Novel Ultrasound Approach Using Superb Microvascular Imaging Technique</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Focal nodular hyperplasia (FNH) in liver is the second common benign hepatic tumor. It&#xD;
      usually shows hypervascular mass on imaging studies and it is not easy to differentiate with&#xD;
      other hypervascular malignant tumor. For diagnosis of FNH, contrast-enhanced ultrasonography&#xD;
      (US) has been used to detect 'spoke-wheel sign', which can be typically seen in FNH. However,&#xD;
      temporal window of vascular phase using contrast-enhanced US (CEUS) is very short (about 10&#xD;
      sec) and coordination of patient's respiration during US exam is absolutely needed. Thus, the&#xD;
      investigators will use Superb-Microvascular imaging (SMI, Toshiba, Japan) for detection of&#xD;
      'spoke-wheel sign' in patients with proven FNH, which enable to detect slow micro vascular&#xD;
      flow without using CEUS.&#xD;
&#xD;
      First, to compare the detection rate of 'spoke-wheel sign' between CEUS using sonazoid&#xD;
      (Perfluorobutane, GE healthcare) and SMI.&#xD;
&#xD;
      Second, to compare the accuracy of size measurement between gray-scale US and SMI (reference&#xD;
      standard: CEUS using sonazoid.)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. To evaluate the detection rate of 'spoke-wheel sign' on CEUS using sonazoid and SMI&#xD;
           (primary outcome).&#xD;
&#xD;
           Each US findings during exam for patients with FNH were recorded by radiologist. The&#xD;
           results were interpreted by consensus using 4 scale bar.&#xD;
&#xD;
           0. Absence of 'spoke-wheel sign'&#xD;
&#xD;
             1. Mild suspicious of 'spoke-wheel sign'&#xD;
&#xD;
             2. Highly suspicious of 'spoke-wheel sign'&#xD;
&#xD;
             3. Definite &quot;spoke-wheel sign'&#xD;
&#xD;
        2. To evaluated the accuracy of size measurement for FNH on gray-scale US and SMI&#xD;
           (reference standard: CEUS using sonazoid).&#xD;
&#xD;
           To calculate the measurement error between each method and CEUS using sonazoid on US&#xD;
           images using measurement of maximum diameter of tumor.&#xD;
&#xD;
        3. Sample size calculation according to the primary outcome.&#xD;
&#xD;
      Expecting the detection rate of &quot;spoke-wheel sign&quot; on SMI, 20% (known detection rate on CEUS&#xD;
      using sonazoid, 23.5%), a sample size of 62 patients was required using 95% confidence&#xD;
      interval.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">April 25, 2019</completion_date>
  <primary_completion_date type="Actual">April 25, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Grading of spoke-wheel sign on CEUS using sonazoid and SMI in patients with focal nodular hyperplasia</measure>
    <time_frame>1 day</time_frame>
    <description>a.To evaluate the detection rate of 'spoke-wheel sign' on CEUS using sonazoid and SMI (primary outcome).&#xD;
Each US findings during exam for patients with FNH were recorded by radiologist. The results were interpreted by consensus using 4 scale bar.&#xD;
0. Absence of 'spoke-wheel sign'&#xD;
Mild suspicious of 'spoke-wheel sign'&#xD;
Highly suspicious of 'spoke-wheel sign'&#xD;
Definite &quot;spoke-wheel sign'</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement error of focal nodular hyperplasia between b-mode US and SMI according to the reference standard, CEUS</measure>
    <time_frame>1 day</time_frame>
    <description>To calculate the measurement error between b-mode US and SMI using measurement of maximum diameter of tumor. Reference standard is the size of tumor on sonazoid enhanced US.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Focal Nodular Hyperplasia</condition>
  <arm_group>
    <arm_group_label>SMI and sonazoid (single arm)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with focal nodular hyperplasia will undergo ultrasonography with Superb-Microvascular imaging and additional sonazoid-enhanced ultrasonography. SMI is a software function in a Toshiba Aplio 500 system. Sonazoid is contrast-material for US and it is a intervention for patient with FNH. Sonazoid will be administered at a dose of 0.015 mL/kg by manual bolus injection, followed by a 10 mL normal saline flush via a peripheral venous line</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sonazoid</intervention_name>
    <description>Sonazoid: Commercially available contrast material for ultrasonography</description>
    <arm_group_label>SMI and sonazoid (single arm)</arm_group_label>
    <other_name>Perfluorobutane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Superb-Microvascular imaging</intervention_name>
    <description>Superb-Microvascular imaging: new sonographic software technique on ultrasonography to detect low-vascular flow without use of contrast media for ultrasonography</description>
    <arm_group_label>SMI and sonazoid (single arm)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Patients with biopsy or imaging proven focal nodular hyperplasia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant women&#xD;
&#xD;
          2. Patient's age &gt; 70&#xD;
&#xD;
          3. Egg allergy&#xD;
&#xD;
          4. Breast-feeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Woo Kyoung Woo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>January 15, 2016</study_first_submitted>
  <study_first_submitted_qc>April 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2016</study_first_posted>
  <last_update_submitted>December 15, 2019</last_update_submitted>
  <last_update_submitted_qc>December 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Woo Kyoung Jeong, MD</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Focal nodular hyperplasia</keyword>
  <keyword>Ultrasonography</keyword>
  <keyword>Superb-Microvascular imaging</keyword>
  <keyword>Contrast-enhanced ultrasonography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Focal Nodular Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Undecided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

